Skip to main content

Table 4 Brief case history of alveolar soft part sarcomas that responded to immunotherapy

From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Age

Diagnosis

Prior Therapies

Best response and Duration of response with Immunotherapy

33

Alveolar Soft Part

Sunitinib, Pazopanib, cabozantinbi, Vandetanib/Everolimus,

Partial Response ×12 months

32

Alveolar Soft Part

Cediranib, Sunitinib

Partial Response ×8 months

Back to article page